Can-Fite BioPharma to Present Namodenoson Obesity Data
Ticker: CANF · Form: 6-K · Filed: Feb 5, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: conference-presentation, drug-data, corporate-update
TL;DR
Can-Fite presenting Namodenoson obesity data at BIO CEO conference Feb 5th.
AI Summary
On February 5, 2025, Can-Fite BioPharma Ltd. announced its participation in the BIO CEO & Investor Conference 2025. The company will present data on the anti-obesity effects of its drug Namodenoson. Additionally, Can-Fite BioPharma has updated its corporate presentation, which is available on its website.
Why It Matters
This presentation highlights potential new applications for Namodenoson, which could expand its market reach and revenue potential if successful.
Risk Assessment
Risk Level: medium — The company is presenting data on a drug's potential effect, which carries inherent clinical and market risks.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant
- Namodenoson (drug) — Drug being presented
- BIO CEO & Investor Conference 2025 (event) — Conference where data will be presented
- February 5, 2025 (date) — Date of press release and conference
FAQ
What specific data on Namodenoson's anti-obesity effects will Can-Fite BioPharma present?
The filing states that Can-Fite BioPharma will present the "Namodenoson Anti-Obesity Effect" at the BIO CEO & Investor Conference 2025, but does not provide specific details of the data within this 6-K.
Where can investors find the updated corporate presentation?
The updated corporate presentation has been posted to Can-Fite BioPharma's website and is furnished as Exhibit 99.2 to this 6-K filing.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer, primarily to furnish a press release announcing the company's participation in the BIO CEO & Investor Conference 2025 and the presentation of Namodenoson data.
Is Can-Fite BioPharma filing an annual report (Form 20-F) or a different form?
Can-Fite BioPharma indicates it files annual reports under Form 20-F.
When was the press release regarding the conference participation issued?
The press release was issued on February 5, 2025.
Filing Stats: 223 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2025-02-05 07:02:36
Filing Documents
- ea0230008-6k_canfite.htm (6-K) — 10KB
- ea023000801ex99-1_canfite.htm (EX-99.1) — 11KB
- ea023000801ex99-2_canfite.htm (EX-99.2) — 27KB
- ex99-2_001.jpg (GRAPHIC) — 1470KB
- ex99-2_002.jpg (GRAPHIC) — 2436KB
- ex99-2_003.jpg (GRAPHIC) — 724KB
- ex99-2_004.jpg (GRAPHIC) — 967KB
- ex99-2_005.jpg (GRAPHIC) — 586KB
- ex99-2_006.jpg (GRAPHIC) — 759KB
- ex99-2_007.jpg (GRAPHIC) — 1080KB
- ex99-2_008.jpg (GRAPHIC) — 1137KB
- ex99-2_009.jpg (GRAPHIC) — 1018KB
- ex99-2_010.jpg (GRAPHIC) — 773KB
- ex99-2_011.jpg (GRAPHIC) — 1092KB
- ex99-2_012.jpg (GRAPHIC) — 1200KB
- ex99-2_013.jpg (GRAPHIC) — 1114KB
- ex99-2_014.jpg (GRAPHIC) — 1098KB
- ex99-2_015.jpg (GRAPHIC) — 896KB
- ex99-2_016.jpg (GRAPHIC) — 1033KB
- ex99-2_017.jpg (GRAPHIC) — 1108KB
- ex99-2_018.jpg (GRAPHIC) — 921KB
- ex99-2_019.jpg (GRAPHIC) — 846KB
- ex99-2_020.jpg (GRAPHIC) — 894KB
- ex99-2_021.jpg (GRAPHIC) — 1101KB
- ex99-2_022.jpg (GRAPHIC) — 984KB
- ex99-2_023.jpg (GRAPHIC) — 987KB
- 0001213900-25-010248.txt ( ) — 33413KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 5, 2025 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3